Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535794 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL5366432 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL14452075 | 0.72 | ALDH1A1 (0.65) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL110817 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL19348924 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL111221 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL5373212 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL106401 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL5370832 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 | |
| SCHEMBL5371920 | 0.72 | LMNA (0.66) | ALDH1A1TSHRLMNAMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8795630-B2 | Butyrylcholinesterase ligands as diagnostic tools and treatment for diseases of the nervous system | TREVENTIS CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2320891-B1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORP (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20110212026-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION | 2011-09-01 | — | — | US | disclosed |
| EP-2320891-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | Treventis Corporation (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010025368-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212026-A1 | BUTYRYLCHOLINESTERASE LIGANDS AS DIAGNOSTIC TOOLS AND TREATMENT FOR DESEASES OF THE NERVOUS SYSTEM | BCHE, ACHE, CERS2 | ALDH1A1 1760/4885TSHR 979/4885LMNA 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.